Zimmer Biomet beats top-line and bottom-line estimates; initiates FY26 outlook and new stock repurchase authorization
Zimmer Biomet beats top-line and bottom-line estimates; initiates FY26 outlook and new stock repurchase authorization
By Press Room
By Press Room
